Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477100 · ClinicalTrials.gov registry record
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
A clinical trial of Invasive Breast Carcinoma and Inflammatory Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 1,200
- Enrollment target
- 10
- Study locations
NCT00477100 is a study of Invasive Breast Carcinoma and Inflammatory Breast Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 1,200 participants, above the 458-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (162% higher). The trial reports 10 study locations across 6 states.
The verdict
NCT00477100, a study of Invasive Breast Carcinoma and Inflammatory Breast Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
- 10
- Study locations
Study Summary
This trial studies the biospecimen and medical data collection in creating a research tissue registry in patients with inflammatory or invasive breast cancer. Collecting medical data and storing samples of blood, tissue, and stool from patients with inflammatory breast cancer to study in the laboratory may help doctors find better ways to treat and study inflammatory breast cancer in the future.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Questionnaire Administration
- OTHER Medical Chart Review
- OTHER Interview
Study Locations (10)
Texas
- M D Anderson Cancer Center - Houston
- MD Anderson in Katy - Houston
- MD Anderson League City - Nassau Bay
- MD Anderson in Sugar Land - Sugar Land
- MD Anderson in The Woodlands - The Woodlands
Arizona
- Banner - MD Anderson Cancer Center - Gilbert
California
- Scripps - MD Anderson Cancer Center - La Jolla
Colorado
- Banner - MD Anderson Cancer Center - Northern Colorado - Greeley
Florida
- Baptist - MD Anderson Cancer Center - Jacksonville
Michigan
- Covenant Medical Center - Saginaw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2007-04-17 |
| Est. Completion | 2030-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477100
The ClinicalTrials.gov registry entry for NCT00477100 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 458-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (162% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT00477100 reports 10 study locations spanning 6 distinct geographic areas - top geographies include Texas, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00477100 about?
NCT00477100 is a clinical study titled "Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer". This trial studies the biospecimen and medical data collection in creating a research tissue registry in patients with inflammatory or invasive breast cancer. Collecting medical data and storing samples of blood, tissue, and stool from patients with inflammatory breast cancer to study in the laborat...
What is the current status of trial NCT00477100?
This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2007-04-17. Estimated completion is 2030-04-30.
What conditions does trial NCT00477100 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma, Inflammatory Breast Carcinoma, Second Primary Malignant Neoplasm.
What interventions are being tested in trial NCT00477100?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Medical Chart Review (OTHER), Interview (OTHER).
Who is sponsoring clinical trial NCT00477100?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00477100 being conducted?
This trial has 10 study locations across Arizona, California, Colorado, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
RECRUITING · Phase 1
-
Breast Cancer Survivorship Biorepository
RECRUITING
-
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
RECRUITING
-
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
RECRUITING · NA
-
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
RECRUITING · Phase 3
-
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.